Literature DB >> 30361242

Can we predict tuberculosis cure? What tools are available?

Delia Goletti1, Cecilia S Lindestam Arlehamn2, Thomas J Scriba3, Richard Anthony4, Daniela Maria Cirillo5, Tonino Alonzi6, Claudia M Denkinger7, Frank Cobelens8.   

Abstract

Antibiotic treatment of tuberculosis takes ≥6 months, putting a major burden on patients and health systems in large parts of the world. Treatment beyond 2 months is needed to prevent tuberculosis relapse by clearing remaining, drug-tolerant Mycobacterium tuberculosis bacilli. However, the majority of patients treated for only 2-3 months will cure without relapse and do not need prolonged treatment. Assays that can identify these patients at an early stage of treatment may significantly help reduce the treatment burden, while a test to identify those patients who will fail treatment may help target host-directed therapies.In this review we summarise the state of the art with regard to discovery of biomarkers that predict relapse-free cure for pulmonary tuberculosis. Positron emission tomography/computed tomography scanning to measure pulmonary inflammation enhances our understanding of "cure". Several microbiological and immunological markers seem promising; however, they still need a formal validation. In parallel, new research strategies are needed to generate reliable tests.
Copyright ©ERS 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30361242     DOI: 10.1183/13993003.01089-2018

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  25 in total

Review 1.  Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies.

Authors:  Jan Heyckendorf; Sophia B Georghiou; Nicole Frahm; Norbert Heinrich; Irina Kontsevaya; Maja Reimann; David Holtzman; Marjorie Imperial; Daniela M Cirillo; Stephen H Gillespie; Morten Ruhwald
Journal:  Clin Microbiol Rev       Date:  2022-03-21       Impact factor: 50.129

2.  Mycobacterium tuberculosis-stimulated whole blood culture to detect host biosignatures for tuberculosis treatment response.

Authors:  Karen Cilliers; Angela Menezes; Tariq Webber; Hazel M Dockrell; Jacqueline M Cliff; Léanie Kleynhans; Novel N Chegou; Nelita du Plessis; André G Loxton; Martin Kidd; Joel Fleury Djoba Siawaya; Katharina Ronacher; Gerhard Walzl
Journal:  Tuberculosis (Edinb)       Date:  2021-04-10       Impact factor: 3.131

3.  PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease.

Authors:  Germana Grassi; Valentina Vanini; Federica De Santis; Alessandra Romagnoli; Alessandra Aiello; Rita Casetti; Eleonora Cimini; Veronica Bordoni; Stefania Notari; Gilda Cuzzi; Silvia Mosti; Gina Gualano; Fabrizio Palmieri; Maurizio Fraziano; Delia Goletti; Chiara Agrati; Alessandra Sacchi
Journal:  Front Immunol       Date:  2021-04-26       Impact factor: 7.561

4.  IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting.

Authors:  Ida Marie Hoel; Melissa Davidsen Jørstad; Msafiri Marijani; Morten Ruhwald; Tehmina Mustafa; Anne Ma Dyrhol-Riise
Journal:  Sci Rep       Date:  2019-03-07       Impact factor: 4.379

5.  Biomarkers of iron metabolism facilitate clinical diagnosis in M ycobacterium tuberculosis infection.

Authors:  Youchao Dai; Wanshui Shan; Qianting Yang; Jiubiao Guo; Rihong Zhai; Xiaoping Tang; Lu Tang; Yaoju Tan; Yi Cai; Xinchun Chen
Journal:  Thorax       Date:  2019-10-14       Impact factor: 9.139

6.  Antibody Subclass and Glycosylation Shift Following Effective TB Treatment.

Authors:  Patricia S Grace; Sepideh Dolatshahi; Lenette L Lu; Adam Cain; Fabrizio Palmieri; Linda Petrone; Sarah M Fortune; Tom H M Ottenhoff; Douglas A Lauffenburger; Delia Goletti; Simone A Joosten; Galit Alter
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561

7.  Multi-country evaluation of RISK6, a 6-gene blood transcriptomic signature, for tuberculosis diagnosis and treatment monitoring.

Authors:  Rim Bayaa; Mame Diarra Bousso Ndiaye; Carole Chedid; Eka Kokhreidze; Nestani Tukvadze; Sayera Banu; Mohammad Khaja Mafij Uddin; Samanta Biswas; Rumana Nasrin; Paulo Ranaivomanana; Antso Hasina Raherinandrasana; Julio Rakotonirina; Voahangy Rasolofo; Giovanni Delogu; Flavio De Maio; Delia Goletti; Hubert Endtz; Florence Ader; Monzer Hamze; Mohamad Bachar Ismail; Stéphane Pouzol; Niaina Rakotosamimanana; Jonathan Hoffmann
Journal:  Sci Rep       Date:  2021-07-01       Impact factor: 4.996

8.  Effect of HIV-infection on QuantiFERON-plus accuracy in patients with active tuberculosis and latent infection.

Authors:  Elisa Petruccioli; Teresa Chiacchio; Assunta Navarra; Valentina Vanini; Gilda Cuzzi; Claudia Cimaglia; Luigi Ruffo Codecasa; Carmela Pinnetti; Niccolò Riccardi; Fabrizio Palmieri; Andrea Antinori; Delia Goletti
Journal:  J Infect       Date:  2020-02-22       Impact factor: 6.072

9.  Tuberculosis bacillary load, an early marker of disease severity: the utility of tuberculosis Molecular Bacterial Load Assay.

Authors:  Wilber Sabiiti; Khalide Azam; Eoghan Charles William Farmer; Davis Kuchaka; Bariki Mtafya; Ruth Bowness; Katarina Oravcova; Isobella Honeyborne; Dimitrios Evangelopoulos; Timothy Daniel McHugh; Celso Khosa; Andrea Rachow; Norbert Heinrich; Elizabeth Kampira; Geraint Davies; Nilesh Bhatt; Elias N Ntinginya; Sofia Viegas; Ilesh Jani; Mercy Kamdolozi; Aaron Mdolo; Margaret Khonga; Martin J Boeree; Patrick P J Phillips; Derek Sloan; Michael Hoelscher; Gibson Kibiki; Stephen H Gillespie
Journal:  Thorax       Date:  2020-04-30       Impact factor: 9.102

10.  Transcriptional biomarkers for predicting development of tuberculosis: progress and clinical considerations.

Authors:  Hanif Esmail; Frank Cobelens; Delia Goletti
Journal:  Eur Respir J       Date:  2020-03-05       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.